Top

International Journal of Clinical Pharmacy

Published in:

01-12-2012 | Commentary

Pharmacists as providers of HIV pre-exposure prophylaxis

Authors: Christine Bruno, Parya Saberi

Published in: International Journal of Clinical Pharmacy | Issue 6/2012

Abstract

The efficacy of HIV pre-exposure prophylaxis (PrEP) has been demonstrated in four clinical trials to date; however, the success of PrEP is largely dependent on high levels of medication adherence. Due to their extensive experience and expertise in medication adherence counseling, as well as their ability to monitor and manage medication adverse effects and drug–drug interactions, clinical pharmacists are well-equipped to play a key role in effective PrEP utilization. Here we discuss reasons favoring the establishment of a protocol-based, pharmacist-run PrEP clinic.

UNAIDS. UNAIDS fact sheet. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS; 2011; Available from: http://www.unaids.org/en/resources/presscentre/factsheets/.

Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168-74.

Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.PubMedCrossRef

Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.PubMedCrossRef

Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34.PubMedCrossRef

Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–22.PubMedCrossRef

Microbicide trials network statement on decision to discontinue use of oral Tenofovir tablets in VOICE, a major HIV prevention study in women.: microbicide trials network; 2011 [4/15/2012]; Available from: http://www.mtnstopshiv.org/node/3619.

Microbicide trials network statement on decision to discontinue use of Tenofovir gel in VOICE, a major HIV prevention study in women.: microbicide trials network; 2011 [4/15/2012]; Available from: http://www.mtnstopshiv.org/node/3909.

Saberi P, Dong BJ, Johnson MO, Greenblatt RM, Cocohoba JM. The impact of HIV clinical pharmacists on HIV treatment outcomes: a systematic review. Patient Preference Adherence. 2012;6:297–322.CrossRef

10.

van der Straten A, Van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS. 2012;26(7):F13–9.PubMedCrossRef

11.

Chisholm-Burns MA, Lee JK, Spivey CA, Slack M, Herrier RN, Hall-Lipsy E, et al. US pharmacists’ effect as team members on patient care systematic review and meta-analyses. Med Care. 2010;48(10):923–33.PubMedCrossRef

12.

McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA. 2002;288(22):2868–79.PubMedCrossRef

13.

Saberi P, Johnson MO. Technology-based self-care methods of improving antiretroviral adherence: a systematic review. PLoS ONE. 2011;6(11):e27533.PubMedCrossRef

14.

Wagner GJ, Ryan GW. Relationship between routinization of daily behaviors and medication adherence in HIV-positive drug users. AIDS Patient Care STDS. 2004;18(7):385–93.PubMedCrossRef

15.

Romano J, editor. PrEP 2: The next generation of drugs and technologies (Paper #69). In: 19th Conference on retroviruses and opportunistic infections. Seattle, WA; 2012. http://retroconference.org/.

16.

Kelesidis T, Landovitz RJ. Preexposure prophylaxis for HIV prevention. Curr HIV/AIDS Rep. 2011;8(2):94–103.PubMedCrossRef

17.

Gilchrist VJ, Stange KC, Flocke SA, McCord G, Bourguet CC. A comparison of the National Ambulatory Medical Care Survey (NAMCS) measurement approach with direct observation of outpatient visits. Med Care. 2004;42(3):276–80.PubMedCrossRef

18.

Hallett TB, Baeten JM, Heffron R, Barnabas R, de Bruyn G, Cremin I, et al. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med. 2011;8(11):e1001123.PubMedCrossRef

19.

Paltiel AD, Freedberg KA, Scott CA, Schackman BR, Losina E, Wang B, et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis. 2009;48(6):806–15.PubMedCrossRef

20.

Malik A, Abraham P, Malik N. Acute renal failure and fanconi syndrome in an AIDS patient on tenofovir treatment—case report and review of literature. J Infect. 2005;51(2):E61–5.PubMedCrossRef

21.

Hall AM, Hendry BM, Nitsch D, Connolly JO. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis. 2011;57(5):773–80.PubMedCrossRef

22.

Scherzer R, Estrella M, Li Y, Choi AI, Deeks SG, Grunfeld C, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS. 2012;26(7):867–75.PubMedCrossRef

23.

March K, Mak M, Louie SG. Effects of pharmacists’ interventions on patient outcomes in an HIV primary care clinic. Am J Health Syst Pharm. 2007;64(24):2574–8.PubMedCrossRef

24.

Santschi V, Chiolero A, Burnand B, Colosimo AL, Paradis G. Impact of pharmacist care in the management of cardiovascular disease risk factors: a systematic review and meta-analysis of randomized trials. Arch Intern Med. 2011;171(16):1441–53.PubMedCrossRef

25.

HIV/AIDS Programme. Guidance on pre-exposure oral prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: Recommendations for use in the context of demonstration projects. In: World Health Organization, editor. 2012. http://apps.who.int/iris/bitstream/10665/75188/1/9789241503884_eng.pdf

26.

Center for Disease Control and Prevention. CDC interim guidance on HIV pre-exposure prophylaxis. Atlanta, GA; 2012. Available from: http://www.cdc.gov/hiv/prep/.

27.

Abbas UL, Anderson RM, Mellors JW. Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLoS ONE. 2007;2(9):e875.PubMedCrossRef

28.

Golub SA, Kowalczyk W, Weinberger CL, Parsons JT. Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr. 2010;54(5):548–55.PubMedCrossRef

29.

Supervie V, Garcia-Lerma JG, Heneine W, Blower S. HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis. Proc Natl Acad Sci USA. 2010;107(27):12381–6.PubMedCrossRef

30.

Vissers DC, Voeten HA, Nagelkerke NJ, Habbema JD, de Vlas SJ. The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa and India: a simulation study. PLoS ONE. 2008;3(5):e2077.PubMedCrossRef

Title: Pharmacists as providers of HIV pre-exposure prophylaxis
Authors: Christine Bruno
Parya Saberi
Publication date: 01-12-2012
Publisher: Springer Netherlands
Published in: International Journal of Clinical Pharmacy / Issue 6/2012
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI: https://doi.org/10.1007/s11096-012-9709-0

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Pharmacists as providers of HIV pre-exposure prophylaxis

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2012

Validation of pharmacogenetic algorithms and warfarin dosing table in Egyptian patients

Optimisation of glycaemic control during episodes of severe/acute hyperglycaemia in patients with type 2 diabetes mellitus

Implementing a clinical pharmacy survey of adverse drug events in a French emergency department

Impact of the sitagliptin alert on prescription of oral antihyperglycemic drugs in Japan

Potential for simplification of HIV treatment with boosted protease inhibitor monotherapy

Prescribing of zoledronic acid in a tertiary outpatient hospital setting

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page